Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Loxoprofen - Daiichi Sankyo Company

Drug Profile

Loxoprofen - Daiichi Sankyo Company

Alternative Names: CS-600G; Loxonin; Loxonin Pap; Loxonin Tape; Loxoprofen gel; Loxoprofen poultice; Loxoprofen sodium; Loxoprofen tape; LX-A; LX-P

Latest Information Update: 22 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Cardinal Health; Daiichi Sankyo Brasil; Daiichi Sankyo Company; Lead Chemical
  • Class Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 15 Oct 2019 Phase-II clinical trials in Pain in Germany (Transdermal) (EudraCT2019-001038-32)
  • 27 Jun 2019 No development reported - Phase-III for Pain in Brazil (Transdermal)
  • 12 Mar 2019 No development reported - Phase-II for Pain (In volunteers) in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top